Alterity Therapeutics Limited

Penelope Jane Huggins

Kevin Jeffrey Barnham

Silas Bond

Antony Vincent Robinson

Jack Gordon Parsons

Elisabeth Colette Louise Gautier

The present invention relates to compounds that have zinc and/or iron ionophore activity and their use in treating diseases that are modulated by reducing zinc and/or iron. In particular embodiments, the compounds are compounds of formula (I): 

Acyl hydrazone derivative compounds for treating disease

The present invention provides heterocyclic compounds of formula (I) that modulate biological metals and to pharmaceutical compositions containing such compounds. The invention particularly relates to compounds that modulate iron and to compounds for the treatment of diseases, particularly neurological diseases such as Parkinson's disease (PD), Alzheimer's disease (AD), Alzheimer-type dementia, Huntington's disease (HD), amyotrophic lateral sclerosis (ALS), frontotemporal dementia (FTD) and multiple system atrophy (MSA). 

Compounds for and methods of treating diseases

The present invention provides compounds that modulate biological metals and to pharmaceutical compositions containing such compounds. The invention particularly relates to imidazo[1,5-a]pyridine compounds of formula (I) that modulate iron and are useful for the treatment of diseases, particularly neurological diseases such as Parkinson's disease (PD), Alzheimer's disease (AD), Alzheimer-type dementia, Huntington's disease (HD), amyotrophic lateral sclerosis (ALS), frontotemporal dementia (FTD) and multiple system atrophy (MSA). The compounds of formula (I) being where variables are defined herein.

Growing community of inventors

Melbourne, Australia

Penelope Jane Huggins